SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    JSH Guidelines for the Management of Hepatitis B Virus Infection, Hepatology Research, 2014, 44,
  2. 2
    Fumitaka Suzuki, Yasuji Arase, Yoshiyuki Suzuki, Norio Akuta, Hitomi Sezaki, Yuya Seko, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada, Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan, Journal of Gastroenterology, 2012, 47, 7, 814

    CrossRef

  3. 3
    Alessandra Maciel Almeida, Anderson Lourenço da Silva, Mariângela Leal Cherchiglia, Eli Iola Gurgel Andrade, Gustavo Laine Araújo de Oliveira, Francisco de Assis Acurcio, Chronic Hepatitis B Treatment: The Cost-Effectiveness of Interferon Compared to Lamivudin e, Value in Health, 2011, 14, 5, S24

    CrossRef

  4. 4
    Osamu Yokosuka, Masayuki Kurosaki, Fumio Imazeki, Yasuji Arase, Yasuhito Tanaka, Kazuaki Chayama, Eiji Tanaka, Hiromitsu Kumada, Namiki Izumi, Masashi Mizokami, Masatoshi Kudo, Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009, Hepatology Research, 2011, 41, 1
  5. 5
    Vincent Rijckborst, Martijn J ter Borg, Yilmaz Cakaloglu, Peter Ferenci, Fehmi Tabak, Meral Akdogan, Krzysztof Simon, Maria Raptopoulou-Gigi, Necati Örmeci, Pieter E Zondervan, Elke Verhey, Anneke J van Vuuren, Bettina E Hansen, Harry LA Janssen, A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B, The American Journal of Gastroenterology, 2010, 105, 8, 1762

    CrossRef

  6. 6
    Helen S. Te, Antiviral Therapy: Analysis of Long-term Efficacy and Safety, Current Hepatitis Reports, 2010, 9, 4, 214

    CrossRef

  7. 7
    Jin Luo, Jun Li, Rui L. Chen, Lei Nie, Jie Huang, Zheng W. Liu, Lin Luo, Xiao J. Yan, Autologus dendritic cell vaccine for chronic hepatitis B carriers: A pilot, open label, clinical trial in human volunteers, Vaccine, 2010, 28, 13, 2497

    CrossRef

  8. 8
    Masashi Mizokami, Eiji Tanaka, Kazuaki Chayama, Yasuhito Tanaka, Masayuki Kurosaki, Namiki Izumi, Yasuji Arase, Hiromitsu Kumada, Fumio Imazeki, Osamu Yokosuka, Masatoshi Kudo, JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B, Kanzo, 2010, 51, 5, 243

    CrossRef

  9. 9
    T. Asselah, O. Lada, P. Marcellin, Résultats des essais thérapeutiques dans l’hépatite chronique B, Antibiotiques, 2010, 12, 1, 42

    CrossRef

  10. 10
    JULES L. DIENSTAG, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  11. 11
    Lise L. Gluud, Christian Gluud, Meta-analyses on Viral Hepatitis, Infectious Disease Clinics of North America, 2009, 23, 2, 315

    CrossRef

  12. 12
    Erik H.C.J. Buster, Solko W. Schalm, Harry L.A. Janssen, Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1093

    CrossRef

  13. 13
    Teerha Piratvisuth, Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B, Hepatology International, 2008, 2, 2, 140

    CrossRef

  14. 14
    T. Asselah, O. Lada, N. Boyer, M. Martinot, P. Marcellin, Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 749

    CrossRef

  15. 15
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  16. 16
    Fumitaka Suzuki, Hiromitsu Kumada, Interferon and lamivudine monotherapy on chronic hepatitis B in Japan, Hepatology Research, 2007, 37,
  17. 17
    G. BALTAYIANNIS, K. KATSANOS, P. KARAYIANNIS, E. V. TSIANOS, Interferon-α therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece, Alimentary Pharmacology & Therapeutics, 2006, 24, 3
  18. 18
    Antonio Craxì, Giorgio Antonucci, Calogero Cammà, Treatment options in HBV, Journal of Hepatology, 2006, 44, S77

    CrossRef

  19. 19
    Jing You, Hong-Ying Cheng, Shou-Ming Yan, Yan-Wei Qiao, Jun-Hua Huang, Bao-Zhang Tang, Guo-Bing Wu, Jun-Yan Qu, Rong-Xue Wu, Lin Zhuang, Yong-Liang Ma, A Randomized, Controlled, Clinical Study of Thymosin Alpha-1 Versus Interferon-Alpha in Chinese Patients with Chronic Hepatitis B Lacking Hepatitis B Envelope Antigen, Journal of the Chinese Medical Association, 2005, 68, 2, 65

    CrossRef

  20. 20
    C. Yurdaydin, H. Bozkaya, H. Çetinkaya, T. Şahin, D. Karaoğuz, M. Törüner, Ö. Erkan, A. O. Heper, E. Erden, A. M. Bozdayi, Ö. Uzunalimoğlu, Lamivudine vs lamivudine and interferon combination treatment of HBeAg(−) chronic hepatitis B, Journal of Viral Hepatitis, 2005, 12, 3
  21. 21
    Chun-Tao Wai, Robert J Fontana, Clinical significance of hepatitis B virus genotypes, variants, and mutants, Clinics in Liver Disease, 2004, 8, 2, 321

    CrossRef

  22. 22
    Tram T Tran, Paul Martin, Hepatitis B: epidemiology and natural history, Clinics in Liver Disease, 2004, 8, 2, 255

    CrossRef

  23. 23
    Robert J. Fontana, Management of Decompensated HBV Cirrhosis: Lamivudine and Beyond, The American Journal of Gastroenterology, 2004, 99, 1, 64

    CrossRef

  24. 24
    Ingolf Schiefke, Chris Klecker, Melanie Maier, Ute Oesen, Gunnar Etzrodt, Andrea Tannapfel, Uwe G. Liebert, Frieder Berr, Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a, Liver International, 2004, 24, 2
  25. 25
    L. D. Saravolatz, D. M. Asmuth, H. H. Nguyen, G. P. Melcher, S. H. Cohen, R. B. Pollard, Treatments for Hepatitis B, Clinical Infectious Diseases, 2004, 39, 9, 1353

    CrossRef

  26. 26
    Y.-H. Huang, J.-C. Wu, T.-T. Chang, I.-J. Sheen, P.-C. Lee, T.-I. Huo, C.-W. Su, Y.-J. Wang, F.-Y. Chang, S.-D. Lee, Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan, Journal of Viral Hepatitis, 2003, 10, 4
  27. 27
    Jay H Hoofnagle, Challenges in therapy of chronic hepatitis B, Journal of Hepatology, 2003, 39, 230

    CrossRef

  28. 28
    M Lagget, M Rizzetto, Current pharmacotherapy for the treatment of chronic hepatitis B, Expert Opinion on Pharmacotherapy, 2003, 4, 10, 1821

    CrossRef

  29. 29
    Chris Westland, William Delaney, Huiling Yang, Shan-shan Chen, Patrick Marcellin, Stephanos Hadziyannis, Robert Gish, John Fry, Carol Brosgart, Craig Gibbs, Michael Miller, Shelly Xiong, Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438., Gastroenterology, 2003, 125, 1, 107

    CrossRef

  30. 30
    Giovanna Fattovich, Natural history of hepatitis B, Journal of Hepatology, 2003, 39, 50

    CrossRef

  31. 31
    Byung Chul Yoo, Joong-Won Park, Hyung Joon Kim, Dong Ho Lee, Young Ju Cha, Sill Moo Park, Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea, Journal of Hepatology, 2003, 38, 1, 98

    CrossRef

  32. 32
    G. A. Niro, T. Santantonio, R. Fontana, M. Insalata, D. Facciorusso, F. Signorile, F. Perri, A. Guastadisegni, D. Gioffreda, O. Palmieri, G. Pastore, A. Andriulli, Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine, Alimentary Pharmacology & Therapeutics, 2003, 18, 9
  33. 33
    Maurizia Rossana Brunetto, Filippo Oliveri, Piero Colombatto, Barbara Coco, Pietro Ciccorossi, Ferruccio Bonino, Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon, Journal of Hepatology, 2003, 39, 164

    CrossRef

  34. 34
    Raquel Muñoz, Gregorio Castellano, Inmaculada Fernández, Maria Victoria Álvarez, Maria Luisa Manzano, Maria Soledad Marcos, Beatriz Cuenca, José A Solı́s-Herruzo, A pilot study of β-interferon for treatment of patients with chronic hepatitis B who failed to respond to α-interferon, Journal of Hepatology, 2002, 37, 5, 655

    CrossRef

  35. 35
    William E Delaney IV, Angeline Bartholomeusz, Stephen A Locarnini, Evolving therapies for the treatment of chronic hepatitis B virus infection, Expert Opinion on Investigational Drugs, 2002, 11, 2, 169

    CrossRef

  36. 36
    Stephanos J Hadziyannis, Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy, Journal of Hepatology, 2002, 36, 2, 280

    CrossRef

  37. 37
    Maurizia Rossana Brunetto, Filippo Oliveri, Barbara Coco, Gioacchino Leandro, Piero Colombatto, Juliana Monti Gorin, Ferruccio Bonino, Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study, Journal of Hepatology, 2002, 36, 2, 263

    CrossRef

  38. 38
    M. L. Funk, D. M. Rosenberg, A. S. F. Lok, World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants, Journal of Viral Hepatitis, 2002, 9, 1
  39. 39
    Otto S. Lin, Emmet B. Keeffe, CURRENTTREATMENTSTRATEGIES FORCHRONICHEPATITISBANDC, Annual Review of Medicine, 2001, 52, 1, 29

    CrossRef

  40. 40
    G. V. Papatheodoridis, S. J. Hadziyannis, Diagnosis and management of pre-core mutant chronic hepatitis B, Journal of Viral Hepatitis, 2001, 8, 5
  41. 41
    C.-C. Lin, J.-C. Wu, T.-T. Chang, Y.-H. Huang, Y.-J. Wang, S.-H. Tsay, N.-H. Chow, F.-Y. Chang, S.-D. Lee, Long-term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan, Journal of Viral Hepatitis, 2001, 8, 6
  42. 42
    Anna S. Lok, E.Jenny Heathcote, Jay H. Hoofnagle, Management of hepatitis B: 2000—Summary of a workshop, Gastroenterology, 2001, 120, 7, 1828

    CrossRef

  43. 43
    Vicente Carreño, Stefan Zeuzem, Uwe Hopf, Patrick Marcellin, W.Graham E. Cooksley, Johan Fevery, Moisés Diago, Rajender Reddy, Marion Peters, Karen Rittweger, Ashok Rakhit, Margarita Pardo, A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B, Journal of Hepatology, 2000, 32, 2, 317

    CrossRef

  44. 44
    Henry L. Y. Chan, Nancy W. Y. Leung, Munira Hussain, May L. Wong, Anna S. F. Lok, Hepatitis B e antigen–negative chronic hepatitis b in Hong Kong, Hepatology, 2000, 31, 3
  45. 45
    Anna Suk-Fong Lok, Hepatitis B infection: Pathogenesis and management, Journal of Hepatology, 2000, 32, 89

    CrossRef

  46. 46
    Andreas Erhardt, Ulf Reineke, Dirk Blondin, Wolfram Hubert Gerlich, Ortwin Adams, Tobias Heintges, Claus Niederau, Dieter Häussinger, Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B, Hepatology, 2000, 31, 3
  47. 47
    Teresa Cotonat, Juan Antonio Quiroga, Juan Manuel López-Alcorocho, Rosa Clouet, Margarita Pardo, Félix Manzarbeitia, Vicente Carreño, Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody–positive patients, Hepatology, 2000, 31, 2
  48. 48
    O. Lo Iacono, M. Fernández Bermejo, Tratamiento de las hepatitis crónicas víricas, Medicine - Programa de Formación Médica Continuada Acreditado, 2000, 8, 13, 686

    CrossRef

  49. 49
    Tiffany Weakley, K. Rajender Reddy, Hepatitis B, Current Treatment Options in Gastroenterology, 1999, 2, 6, 463

    CrossRef

  50. 50
    Mandana Khalili, Robert P. Perrillo, INTERFERON THERAPY OF HEPATITIS B, Clinics in Liver Disease, 1999, 3, 2, 363

    CrossRef

  51. 51
    Filippo Oliveri, Teresa Santantonio, Giorgio Bellati, Piero Colombatto, Guido Colloredo Mels, Luigi Carriero, Giuseppe Dastoli, Giuseppe Pastore, Gaetano Ideo, Ferruccio Bonino, Maurizia Rossana Brunetto, Long term response to therapy of chronic anti-HBe-positive Hepatitis B is poor independent of type and schedule of interferon, The American Journal of Gastroenterology, 1999, 94, 5, 1366

    CrossRef

  52. 52
    Torre, Naoumov, Clinical implications of mutations in the hepatitis B virus genome , European Journal of Clinical Investigation, 1998, 28, 8
    Direct Link:
  53. 53
    Alexandra Alexopoulou, Ania M. Owsianka, Georgia Kafiri, Spyros P. Dourakis, William F. Carman, Stephanos J. Hadziyannis, Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B, Journal of Hepatology, 1998, 29, 3, 345

    CrossRef

  54. 54
    S. Lobello, U. Lorenzoni, A. Vian, A. Floreani, M. R. Brunetto, M. Chiaramonte, Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring, Journal of Viral Hepatitis, 1998, 5, 1
    Direct Link:
  55. 55
    RAJ KUMAR C GUPTAN, VARSHA THAKUR, VEENA MALHOTRA, SHIV K SARIN, Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians, Journal of Gastroenterology and Hepatology, 1998, 13, 7
  56. 56
    Haruki Kondo, Yuji Kasahara, Prevention of severe hepatic injury by interferon-α in chronic active hepatitis lacking HBeAg (mutant strain) in a patient with malignant lymphoma, Cancer Letters, 1998, 125, 1-2, 171

    CrossRef

  57. 57
    Yuji Miura, Hideyuki Takamatsu, Hirokazu Okumura, Takashi Yoshida, Shinji Nakao, Tamotsu Matsuda, Allogeneic bone marrow transplantation for a patient complicated by chronic hepatitis due to precore mutant hepatitis B virus: Failure of management with interferon-α therapy, American Journal of Hematology, 1997, 54, 4
  58. 58
    J. M. Lopez-Alcorocho, J. Bartolome, T. Cotonat, V. Carreño, Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy, Journal of Viral Hepatitis, 1997, 4,
  59. 59
    William M. Lee, Hepatitis B Virus Infection, New England Journal of Medicine, 1997, 337, 24, 1733

    CrossRef

  60. 60
    H. E. Blum, Hepatitis viruses: genetic variants and clinical significance, International Journal of Clinical & Laboratory Research, 1997, 27, 2-4, 213

    CrossRef

  61. 61
    P. Marcellin, N. Giuily, M. A. Loriot, F. Durand, D. Samuel, L. Bettan, C. Degott, J. Bernuau, J. P. Benhamou, S. Erlinger, Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis, Journal of Viral Hepatitis, 1997, 4,
  62. 62
    Makoto Kako, Koichi Kanai, Tatsuya Aikawa, Shogo Iwabuchi, Yasunori Takehira, Tsunehisa Kawasaki, Hirohito Tsubouchi, Kunihiko Hino, Fumio Tsuda, Hiroaki Okamoto, Yuzo Miyakawa, Makoto Mayumi, Response to Interferon-α2a in Patients with e Antigen-Negative Chronic Hepatitis B, Journal of Clinical Gastroenterology, 1997, 25, 2, 440

    CrossRef

  63. 63
    Alastair J.J. Wood, Jay H. Hoofnagle, Adrian M. Di Bisceglie, The Treatment of Chronic Viral Hepatitis, New England Journal of Medicine, 1997, 336, 5, 347

    CrossRef

  64. 64
    Yasuji Arase, Kazuaki Chayama, Akihito Tsubota, Naoya Murashima, Yoshiyuki Suzuki, Isao Koida, Masahiro Kobayashi, Satoshi Saitoh, Kenji Ikeda, Hiromitsu Kumada, Mariko Kobayashi, Hiroshi Suzuki, A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels, Journal of Gastroenterology, 1996, 31, 4, 559

    CrossRef

  65. 65
    G. Rasi, M. G. Mutchnick, D. Di Virgilio, P. Sinibaldi-Vallebona, P. Pierimarchi, F. Colella, C. Favalli, E. Garaci, Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B, Journal of Viral Hepatitis, 1996, 3, 4
  66. 66
    Maria Buti, Rosendo Jardi, Francisco Rodriguez-Frias, Helena Allende, Montserrat Cotrina, Rafael Esteban, Jaime Guardia, Interferon vs. adenine arabinoside 5′-monophosphate in patients with anti-HBe-positive chronic hepatitis, Journal of Medical Virology, 1996, 49, 4
  67. 67
    Maria Guido, Massimo Rugge, Liliana Chemello, Gioacchino Leandro, Giovanna Fattovich, Giuliano Giustina, Mauro Cassaro, Alfredo Alberti, Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy, Journal of Hepatology, 1996, 24, 3, 301

    CrossRef

  68. 68
    G. Giustina, G. Fattovich, M. De Paoli, M. Guido, S. Favarato, M. Rugge, A. Alberti, A. Ruol, M. Plebani, Serum procollagen type III peptide in chronic hepatitis B, International Journal of Clinical and Laboratory Research, 1996, 26, 1, 33

    CrossRef

  69. 69
    Mariano Malaguarnera, Salvatore Restuccia, Giuseppe Receputo, Ignazio Giugno, Giovanni Pistone, Barbara A. Trovato, The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis, Current Therapeutic Research, 1996, 57, 9, 646

    CrossRef

  70. 70
    Giovanna Fattovich, Graham McIntyre, Mark Thursz, Kathryn Colman, Giustina Giuliano, Alfredo Alberti, Howard C. Thomas, William F. Carman, Hepatitis B virus precore/core variation and interferon therapy, Hepatology, 1995, 22, 5
  71. 71
    T. Aikawa, K. Kanai, M. Kako, T. Kawasaki, K. Hino, S. Iwabuchi, H. Tsubouchi, Y. Takehira, F. Tsuda, H. Okamoto, Y. Miyakawa, M. Mayumi, Interferon-α2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild-type virus and precore mutant, Journal of Viral Hepatitis, 1995, 2, 5
  72. 72
    Hanns F. Löhr, Wolfgang Weber, Jörg Schlaak, Bernd Goergen, Karl-Hermann Meyer Zum Büschenfelde, Guido Gerken, Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e–minus hepatitis B virus mutants, Hepatology, 1995, 22, 1
  73. 73
    G Saracco, M Rizzetto, Recent results in the treatment of chronic B virus hepatitis, Biomedicine & Pharmacotherapy, 1995, 49, 2, 55

    CrossRef

  74. 74
    Giovanna Fattovich, Giuliano Giustina, Alfredo Alberti, Maria Guido, Patrizia Pontisso, Susanna Favarato, Luisa Benvegnù, Arturo Ruol, A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B, Journal of Hepatology, 1994, 21, 3, 361

    CrossRef

  75. 75
    Jean Pierre Zarski, Patrick Marcellin, Marielle Cohard, Jean Michel Lutz, Catherine Bouche, Abbès Rais, Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France, Journal of Hepatology, 1994, 20, 5, 636

    CrossRef

  76. 76
    Alfredo Alberti, Giovanna Fattovich, Interferon therapy for the anti-HBe positive form of chronic hepatitis B, Antiviral Research, 1994, 24, 2-3, 145

    CrossRef

  77. 77
    Hanns Löhr, Bernd Goergen, Wolfgang Weber, Werner Godderz, Karl-Hermann Meyer zum Büschenfelde, Guido Gerken, Mixed cryoglobulinemia type II in chronic hepatitis B associated with HBe-minus HBV mutant: Cellular immune reactions and response to interferon treatment, Journal of Medical Virology, 1994, 44, 4
  78. 78
    G. M. DUSHEIKO, Rolling review–the pathogenesis, diagnosis and management of viral hepatitis, Alimentary Pharmacology & Therapeutics, 1994, 8, 2
  79. 79
    David K.H. Wong, Jenny Heathcote, The role of interferon in the treatment of viral hepatitis, Pharmacology & Therapeutics, 1994, 63, 2, 177

    CrossRef

  80. 80
    A. S. F. Lok, Treatment of chronic hepatitis B, Journal of Viral Hepatitis, 1994, 1, 2
  81. 81
    Patrick Marcellin, Jean-Pierre Benhamou, Treatment of chronic viral hepatitis, Baillière's Clinical Gastroenterology, 1994, 8, 2, 233

    CrossRef

  82. 82
    Chronic hepatitis, Disease-a-Month, 1993, 39, 2, 59

    CrossRef

  83. 83
    Humberto Saconato, Carlos Rodrigues da Silva Filho, Álvaro N Atallah, Eduardo R Parise, Alpha-interferon for chronic hepatitis B, The Cochrane Library,
  84. 84
    Humberto Saconato, Carlos Rodrigues da Silva Filho, Álvaro N Atallah, Eduardo R Parise, Alpha-interferon for chronic hepatitis B, The Cochrane Library,
  85. 85
    Piero Luigi Almasio, Calogero Cammà, Vito Di Marco, Antonio Craxì, Hepatitis B: Prognosis and Treatment,